東華大學圖書館 |

Compulsory Licensing of Patented Pharmaceuticals in the Developing World: A Legitimate or Illegitimate Way to Enhance the Access to Medicines?

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Compulsory Licensing of Patented Pharmaceuticals in the Developing World: A Legitimate or Illegitimate Way to Enhance the Access to Medicines?/
作者:	Le, Vu Van Anh.
出版者:	Ann Arbor : ProQuest Dissertations & Theses, : 2018,
面頁冊數:	404 p.
附註:	Source: Dissertations Abstracts International, Volume: 82-08, Section: B.
Contained By:	Dissertations Abstracts International82-08B.
標題:	Public health. -
電子資源:	https://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=28214640
ISBN:	9798684678264

Compulsory Licensing of Patented Pharmaceuticals in the Developing World: A Legitimate or Illegitimate Way to Enhance the Access to Medicines?
Le, Vu Van Anh.

Compulsory Licensing of Patented Pharmaceuticals in the Developing World: A Legitimate or Illegitimate Way to Enhance the Access to Medicines? - Ann Arbor : ProQuest Dissertations & Theses, 2018 - 404 p.

Source: Dissertations Abstracts International, Volume: 82-08, Section: B.

Thesis (Ph.D.)--Bangor University (United Kingdom), 2018.

This item must not be sold to any third party vendors.

The objective of this thesis is to examine the implementation by three carefully selected developing countries of one of the most significant and controversial TRIPS flexibilities - compulsory licensing - so as to meet their differing pharmaceutical needs. This objective will be achieved by adopting a comparative approach between international (TRIPS) and domestic (India, Brazil and Thailand) patent laws, and by conducting a cross-national study of these patent regimes. This thesis critically evaluates the compulsory licensing mechanism of the aforementioned countries, each considered to be an emerging economy, capable of challenging the dominance of OECD nations.The findings suggest that each country's application of compulsory licensing is closely linked to two factors: how it has implemented TRIPS and, its pharmaceutical manufacturing capacity. Where a state capitalises on TRIPS flexibilities and has a well-developed manufacturing capacity, it is unlikely to use compulsory licensing (e.g. India). In contrast, where TRIPS flexibilities are underutilised combined with a low industrial development, then the grant of compulsory licences is highly likely (e.g. Brazil and Thailand). On the one hand, all the compulsory licence grants, to some extent, produced significant effects on society. In the short-term run, these licences eroded the monopoly of patent holding companies, driving down the price of medicine, thereby increasing the number of patients in treatment. Furthermore, as regards India and Brazil, mandatory licensing also resulted in price deductions for other medicines which were not subject to the compulsory licence. Somewhat surprisingly, in all three country case studies, the generics were not made at the cheapest price, compared with the substitutes available on the market, an important consideration for parties seeking a compulsory licence.This work concludes that each country case study has developed its own distinctive regime. The fact that India's compulsory licences were initiated by private companies signifies that this legal tool has mainly served its thriving pharmaceutical industry. An absence of governmental participation in India has caused the country's mandatory licensing to be seen as purely a legal issue. Meanwhile, Brazil and Thailand applied government use licences to respond to their national health needs. This gave a strong political hue to the compulsory licensing regimes in those countries, particularly Thailand's. While Brazil efficiently employed these licences as strategic threats in return for price cuts offered by patent holding companies, the seven licences issued by Thailand's post-coup government are considered extraordinary. It was viewed that an unlawful government was trying to curry favour with the Thai people. The legitimacy of the Thai licences was placed in significant doubt. Given each country's unique characteristics, it is clear that compulsory licensing should not be regarded as a 'one-size-fits-all' solution to combat all healthcare issues in less-developed nations.In addition, this work seeks to achieve a secondary objective of critically evaluating the position of the following multilateral organisations on the issue of compulsory licensing of pharmaceutical products: the EU, WIPO, the WHO, and health-related NGOs. While the EU has built an image as a quiet and tactful player, WIPO displays subtle opposition to compulsory licensing. The WHO attempts to maintain a neutral stance in the ongoing deliberations while the NGOs want to dismantle any barriers to the access to medicines, created by TRIPS.

ISBN: 9798684678264Subjects--Topical Terms:

534748
Public health.
Subjects--Index Terms:

Compulsory licensing

Compulsory Licensing of Patented Pharmaceuticals in the Developing World: A Legitimate or Illegitimate Way to Enhance the Access to Medicines?
LDR:04924nmm a2200373 4500 001 2280631
005 20210907071116.5
008 220723s2018 ||||||||||||||||| ||eng d
020 $a 9798684678264
035 $a (MiAaPQ)AAI28214640
035 $a (MiAaPQ)Bangor_studentthesesb542d093-6eff-4f81-a138-a666c8485c9b
035 $a AAI28214640
040 $a MiAaPQ $c MiAaPQ
100 1 $a Le, Vu Van Anh. $3 3559167
245 1 0 $a Compulsory Licensing of Patented Pharmaceuticals in the Developing World: A Legitimate or Illegitimate Way to Enhance the Access to Medicines?
260 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2018
300 $a 404 p.
500 $a Source: Dissertations Abstracts International, Volume: 82-08, Section: B.
500 $a Advisor: Hyland, Mark;Shi, Wei.
502 $a Thesis (Ph.D.)--Bangor University (United Kingdom), 2018.
506 $a This item must not be sold to any third party vendors.
520 $a The objective of this thesis is to examine the implementation by three carefully selected developing countries of one of the most significant and controversial TRIPS flexibilities - compulsory licensing - so as to meet their differing pharmaceutical needs. This objective will be achieved by adopting a comparative approach between international (TRIPS) and domestic (India, Brazil and Thailand) patent laws, and by conducting a cross-national study of these patent regimes. This thesis critically evaluates the compulsory licensing mechanism of the aforementioned countries, each considered to be an emerging economy, capable of challenging the dominance of OECD nations.The findings suggest that each country's application of compulsory licensing is closely linked to two factors: how it has implemented TRIPS and, its pharmaceutical manufacturing capacity. Where a state capitalises on TRIPS flexibilities and has a well-developed manufacturing capacity, it is unlikely to use compulsory licensing (e.g. India). In contrast, where TRIPS flexibilities are underutilised combined with a low industrial development, then the grant of compulsory licences is highly likely (e.g. Brazil and Thailand). On the one hand, all the compulsory licence grants, to some extent, produced significant effects on society. In the short-term run, these licences eroded the monopoly of patent holding companies, driving down the price of medicine, thereby increasing the number of patients in treatment. Furthermore, as regards India and Brazil, mandatory licensing also resulted in price deductions for other medicines which were not subject to the compulsory licence. Somewhat surprisingly, in all three country case studies, the generics were not made at the cheapest price, compared with the substitutes available on the market, an important consideration for parties seeking a compulsory licence.This work concludes that each country case study has developed its own distinctive regime. The fact that India's compulsory licences were initiated by private companies signifies that this legal tool has mainly served its thriving pharmaceutical industry. An absence of governmental participation in India has caused the country's mandatory licensing to be seen as purely a legal issue. Meanwhile, Brazil and Thailand applied government use licences to respond to their national health needs. This gave a strong political hue to the compulsory licensing regimes in those countries, particularly Thailand's. While Brazil efficiently employed these licences as strategic threats in return for price cuts offered by patent holding companies, the seven licences issued by Thailand's post-coup government are considered extraordinary. It was viewed that an unlawful government was trying to curry favour with the Thai people. The legitimacy of the Thai licences was placed in significant doubt. Given each country's unique characteristics, it is clear that compulsory licensing should not be regarded as a 'one-size-fits-all' solution to combat all healthcare issues in less-developed nations.In addition, this work seeks to achieve a secondary objective of critically evaluating the position of the following multilateral organisations on the issue of compulsory licensing of pharmaceutical products: the EU, WIPO, the WHO, and health-related NGOs. While the EU has built an image as a quiet and tactful player, WIPO displays subtle opposition to compulsory licensing. The WHO attempts to maintain a neutral stance in the ongoing deliberations while the NGOs want to dismantle any barriers to the access to medicines, created by TRIPS.
590 $a School code: 8864.
650 4 $a Public health. $3 534748
650 4 $a Medicine. $3 641104
650 4 $a Pharmaceutical sciences. $3 3173021
653 $a Compulsory licensing
653 $a Patented pharmaceuticals
653 $a Developing world
653 $a Medicine access
690 $a 0564
690 $a 0572
690 $a 0573
710 2 $a Bangor University (United Kingdom). $3 3546296
773 0 $t Dissertations Abstracts International $g 82-08B.
790 $a 8864
791 $a Ph.D.
792 $a 2018
793 $a English
856 4 0 $u https://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=28214640